See more : Burford Capital Limited (BUR.L) Income Statement Analysis – Financial Results
Complete financial analysis of Apexigen, Inc. (APGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apexigen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Renasant Corporation (RNST) Income Statement Analysis – Financial Results
- Tullow Oil plc (TUWLF) Income Statement Analysis – Financial Results
- Redwood Group International, Inc. (RDWD) Income Statement Analysis – Financial Results
- INTLOOP Inc. (9556.T) Income Statement Analysis – Financial Results
- Laboro.AI Inc. (5586.T) Income Statement Analysis – Financial Results
Apexigen, Inc. (APGN)
About Apexigen, Inc.
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.04M | 21.66M | 18.77M |
| General & Administrative | 9.65M | 7.29M | 5.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 9.65M | 7.29M | 5.77M |
| Other Expenses | 617.00K | 0.00 | 0.00 |
| Operating Expenses | 32.69M | 28.96M | 24.54M |
| Cost & Expenses | 32.69M | 28.96M | 24.54M |
| Interest Income | 0.00 | 41.00K | 421.00K |
| Interest Expense | -617.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 110.00K | 105.00K | 127.00K |
| EBITDA | -32.58M | -28.85M | -24.42M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.69M | -28.96M | -24.54M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 617.00K | 41.00K | 421.00K |
| Income Before Tax | -32.07M | -28.92M | -24.12M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -617.00K | -41.00K | -421.00K |
| Net Income | -31.45M | -28.88M | -23.70M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -1.59 | -0.93 | -0.76 |
| EPS Diluted | -1.59 | -0.93 | -0.76 |
| Weighted Avg Shares Out | 19.79M | 31.07M | 31.07M |
| Weighted Avg Shares Out (Dil) | 19.79M | 31.07M | 31.07M |
APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apexigen, Inc. (NasdaqCM: APGN) to Pyxis Oncology, Inc. (NasdaqGS: PYXS). Under...
Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
- Marked increases in overall survival observed across soft tissue sarcoma patients - - Demonstrated improvement of median progression free survival in patients with dedifferentiated liposarcoma (DDLPS) - - DDLPS expansion cohort enrolling to inform a potential Phase 3 registration...
APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apexigen, Inc. (NasdaqCM: APGN) to Pyxis Oncology, Inc. (NasdaqGS: PYXS). Under...
Apexigen (APGN) to Get Acquired by Pyxis Oncology, Stock Up
Apexigen (APGN) surges as Pyxis Oncology offers to acquire it for approximately $16 million.
Shareholder Alert: Ademi LLP investigates whether Apexigen, Inc. has obtained a Fair Price in its transaction with Pyxis Oncology
MILWAUKEE , May 24, 2023 /PRNewswire/ -- Ademi LLP is investigating Apexigen (Nasdaq: APGN) for possible breaches of fiduciary duty and other violations of law in its transaction with Pyxis Oncology. Click here to learn how to join the action https://www.ademilaw.com/case/apexigen-inc or...
Why Is Apexigen (APGN) Stock Up 31% Today?
Apexigen (NASDAQ: APGN ) stock is rising higher on Wednesday following news of a deal with Pyxis Oncology (NASDAQ: PYXS ). This deal has Pyxis Oncology agreeing to acquire Apexigen for 0.1725 shares of PYXS stock for each share of...
APGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Apexigen, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Apexigen, Inc. (NASDAQ: APGN) to Pyxis Oncology, Inc. for 0.1725 shares of Pyxis for each share of Apexigen is fair to Apexigen shareholders. Upon...
APGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Apexigen, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Apexigen, Inc. (NASDAQ: APGN) to Pyxis Oncology, Inc. for 0.1725 shares of Pyxis for each share of Apexigen is fair to Apexigen shareholders. Upon...
Are Medical Stocks Lagging Apexigen, Inc. (APGN) This Year?
Here is how Apexigen, Inc. (APGN) and Atara Biotherapeutics (ATRA) have performed compared to their sector so far this year.
Apexigen Announces Review of Strategic Alternatives and Restructuring
SAN CARLOS, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (Nasdaq: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that it has engaged Ladenburg Thalmann...
Source: https://incomestatements.info
Category: Stock Reports